By Destiny Obinna
The National Agency for Food and Drug Administration and Control (NAFDAC) has dismissed reports circulating on social media that antimalarial drug Camosunate has been banned in Nigeria, describing the claim as false.
The agency said it had never banned Camosunate or any medicine containing the artesunate-amodiaquine combination, urging Nigerians to disregard the misleading information and avoid spreading unnecessary panic.
Camosunate is an antimalarial medicine containing artesunate and amodiaquine.
In a statement signed by its Director-General, Prof. Mojisola Adeyeye, NAFDAC acknowledged that some of the symptoms highlighted in the viral message could be associated with known side effects of the drug.
These include nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness, drowsiness and loss of appetite.
However, the agency stressed that reports of suspected adverse drug reactions should be properly investigated rather than used to promote unverified claims about a ban.
It urged members of the public and healthcare professionals to report suspected reactions through the NAFDAC Med Safety App, available on Android and iOS devices, or at the nearest NAFDAC office.
NAFDAC also appealed to Nigerians who had shared the misleading claim to help correct the misinformation by circulating its clarification through the same social media channels.
The agency said the clarification was necessary to prevent unnecessary public concern and ensure that information about medicines was based on verified regulatory guidance.
